lncRNA LINC01315 promotes malignancy of triple-negative breast cancer and predicts poor outcomes by modulating microRNA-876-5p/GRK5

References

• Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247–269.
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.
   PubMed Web of Science ®Google Scholar
• Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279–287.
   PubMed Web of Science ®Google Scholar
• Robinson EK, Covarrubias S, Carpenter S. The how and why of lncRNA function: an innate immune perspective. Biochim Biophys Acta Gene Regul Mech. 2020;1863(4):194419.
   PubMed Web of Science ®Google Scholar
• Wang J, Bian Q, Liu J, et al. Identification and in vitro validation of prognostic lncRNA signature in head and neck squamous cell carcinoma. Bioengineered. 2021;12(2):10049–10062.
   PubMed Web of Science ®Google Scholar
• Song J, Sun Y, Cao H, et al. A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma. Bioengineered. 2021;12(1):5932–5949.
   PubMed Web of Science ®Google Scholar
• Volovat SR, Volovat C, Hordila I, et al. MiRNA and LncRNA as potential biomarkers in triple-negative breast cancer: a review. Front Oncol. 2020;10:526850.
   PubMed Web of Science ®Google Scholar
• De Palma FDE, Del Monaco V, Pol JG, et al. The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome. Pharmacol Res. 2020;161:105249.
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang N, Song P, et al. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020;53(9):e12855.
   PubMed Web of Science ®Google Scholar
• Naorem LD, Prakash VS, Muthaiyan M, et al. Comprehensive analysis of dysregulated lncRNAs and their competing endogenous RNA network in triple-negative breast cancer. Int J Biol Macromol. 2020;145:429–436.
   PubMed Web of Science ®Google Scholar
• Van Grembergen O, Bizet M, de Bony EJ, et al. Portraying breast cancers with long noncoding RNAs. Sci Adv. 2016;2(9):e1600220.
   PubMed Web of Science ®Google Scholar
• Chen FB, Wu P, Zhou R, et al. LINC01315 impairs microRNA-211-Dependent DLG3 downregulation to inhibit the development of oral squamous cell carcinoma. Front Oncol. 2020;10:556084.
   PubMed Web of Science ®Google Scholar
• Ren J, Zhang FJ, Wang JH, et al. LINC01315 promotes the aggressive phenotypes of papillary thyroid cancer cells by sponging miR-497-5p. Kaohsiung J Med Sci. 2021;37(6):459–467.
   PubMed Web of Science ®Google Scholar
• Liang R, Zhang J, Zhang RM, et al. LINC01315 silencing inhibits the aggressive phenotypes of colorectal carcinoma by sponging miR-205-3p. Biochem Biophys Res Commun. 2021;534:1033–1039.
   PubMed Web of Science ®Google Scholar
• Xu J, Zheng J, Wang J, et al. miR-876-5p suppresses breast cancer progression through targeting TFAP2A. Exp Ther Med. 2019;18(2):1458–1464.
   PubMed Web of Science ®Google Scholar
• Dong G, Pan T, Zhou D, et al. FBXL19-AS1 promotes cell proliferation and inhibits cell apoptosis via miR-876-5p/FOXM1 axis in breast cancer. Acta Biochim Biophys Sin (Shanghai). 2019;51(11):1106–1113.
   PubMed Web of Science ®Google Scholar
• Fu Y, Hu X, Gao Y, et al. LncRNA ROR/miR-145-5p axis modulates the osteoblasts proliferation and apoptosis in osteoporosis. Bioengineered. 2021;12(1):7714–7723.
   PubMed Web of Science ®Google Scholar
• Han P, Zhao J, Gao L. Increased serum exosomal long non-coding RNA SNHG15 expression predicts poor prognosis in non-small cell lung cancer. J Clin Lab Anal. 2021;35(11):e23979.
   PubMed Web of Science ®Google Scholar
• Xu P, Xu H, Cheng HS, et al. MicroRNA 876-5p modulates EV-A71 replication through downregulation of host antiviral factors. Virol J. 2020;17(1):21.
   PubMed Web of Science ®Google Scholar
• Zhai Z, Mu T, Zhao L, et al. MiR-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN/AKT pathway. Bioengineered. 2022;13(1):83–95.
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen W, Gong Y, et al. Tetraspanin 1 (TSPAN1) promotes growth and transferation of breast cancer cells via mediating PI3K/Akt pathway. Bioengineered. 2021;12(2):10761–10770.
   PubMed Web of Science ®Google Scholar
• Al-Mahmood S, Sapiezynski J, Garbuzenko OB, et al. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018;8(5):1483–1507.
   PubMed Web of Science ®Google Scholar
• He MY, Rancoule C, Rehailia-Blanchard A, et al. Radiotherapy in triple-negative breast cancer: current situation and upcoming strategies. Crit Rev Oncol Hematol. 2018;131:96–101.
   PubMed Web of Science ®Google Scholar
• Thakur KK, Kumar A, Banik K, et al. Long noncoding RNAs in triple-negative breast cancer: a new frontier in the regulation of tumorigenesis. J Cell Physiol. 2021;236(12):7938–7965.
   PubMed Web of Science ®Google Scholar
• Wang D, Song Q, Zhao T, et al. Long non-coding RNA MRPS30 divergent transcript can be detected in the cytoplasm of triple-negative breast cancer cells and is targeted by microRNA-130b. Bioengineered. 2022;13(3):5954–5961.
   PubMed Web of Science ®Google Scholar
• Li Y, Ma HY, Hu XW, et al. LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway. Cancer Cell Int. 2020;20(1):200.
   PubMed Web of Science ®Google Scholar
• Song X, Liu Z, Yu Z. LncRNA NEF is downregulated in triple negative breast cancer and correlated with poor prognosis. Acta Biochim Biophys Sin (Shanghai). 2019;51(4):386–392.
   PubMed Web of Science ®Google Scholar
• Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106.
   PubMed Web of Science ®Google Scholar
• Fan CN, Ma L, Liu N. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer. J Transl Med. 2018;16(1):264.
   PubMed Web of Science ®Google Scholar
• Luo H, Xu C, Le W, et al. lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNA-150. J Cell Biochem. 2019;120(8):13487–13493.
   PubMed Web of Science ®Google Scholar
• Sommer AK, Falcenberg M, Ljepoja B, et al. Downregulation of GRK5 hampers the migration of breast cancer cells. Sci Rep. 2019;9(1):15548.
   PubMed Web of Science ®Google Scholar
• Lai HW, Kuo SJ, Chen LS, et al. Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. Eur J Surg Oncol. 2011;37(1):18–24.
   PubMed Web of Science ®Google Scholar
• de Paula BHR, Kumar S, Morosini FM, et al. Real-world assessment of the effect of impact of tumor size on pathological complete response rates in triple negative breast cancer after neoadjuvant chemotherapy. Chin Clin Oncol. 2020;9(6):78.
   PubMed Web of Science ®Google Scholar
• Hashmi AA, Hashmi KA, Irfan M, et al. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes. 2019;12(1):605.
   PubMed Web of Science ®Google Scholar
• Papageorgiou SN. On the sample size of clinical trials. J Orthod. 2018;45(3):210–212.
   PubMed Web of Science ®Google Scholar
• Brown TM. Power and sample size in clinical studies. Journal of nuclear cardiology: official publication of the American Society of Nuclear Cardiology. 2015;22(6):1314–1315.
   PubMed Web of Science ®Google Scholar